Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Microns strong quarterly results and above-consensus outlook, tied to AI-driven memory demand, dominate the discussion. Bulls point to tighter expected supply and continued growth, while many traders are frustrated by the muted stock reaction and argue the beat was priced in; skeptics question how long elevated margins and the memory upcycle can last.

Alphabets Project Suncatcher orbital AI-chip test is a major focus, with traders viewing space-based computing as a potential extension of its AI infrastructure while skeptics call the project speculative. Gemini 4 expectations also feature prominently, amid frustration over volatile trading and the stocks difficulty holding gains.

AppLovins selloff is being tied to bearish analyst commentary questioning e-commerce pixel adoption and growth in its AXON/MAX ad business, with competition from Unity and the companies data-collection dispute adding to concerns. Bulls dispute the slowdown narrative and point to improving adoption and strong fundamentals, while bears focus on growth risks and continued technical weakness.

GOOG is drawing attention amid volatile trading around Googles Gemini AI rollout, with traders debating whether the new model can strengthen its competitive position or whether Metas Muse and broader AI competition threaten Googles business. Bulls cite Googles AI capabilities and infrastructure, while skeptics point to fading price momentum and risks to search and advertising.

A newly adopted executive change-of-control severance policy has reignited buyout and strategic-investment speculation, though traders disagree on whether it signals a deal or is routine governance, and no buyer or transaction is confirmed. Investors are also focused on BlueBird shipment updates and the lack of a firm launch date, with concerns about deployment cadence weighing against optimism about the satellite rollout.

New 24-month HOPE-3 extension data showing slower upper-limb decline among Duchenne patients treated with deramiocel has fueled interest in Capricor. Traders see the results as supportive of the therapy ahead of the FDA decision, while others argue they may not resolve the agencys prior statistical concerns; short-squeeze talk remains speculative.

A Delaware judge ruled that Liquidias Yutrepia infringes two valid United Therapeutics patent claims, raising the risk of removing its PH-ILD indication or restricting availability while remedies are decided. Traders largely fear substantial business and share-price downside, while some call the selloff an overreaction and point to a possible appeal or settlement.

A sharp, high-volume breakout above a long-watched resistance level has fueled attention, with traders pointing to IBRXs short interest as potential squeeze fuel. Others question whether the move can hold without fresh company news; Anktivas pending FDA label-expansion review remains a longer-term catalyst in the discussion.

Bullish analyst coverage and upgrades, citing strong AI-compute demand and pricing, are fueling optimism around CoreWeave, alongside attention to its Nvidia-related product announcements. Traders remain divided as the stock struggles to hold gains: bulls point to demand and contract potential, while bears focus on debt, capital needs, and dilution.

FERCs delay of PJMs proposed capacity procurement is weighing on CEG and renewing uncertainty about how the grid will meet AI-driven power demand and allocate costs. Traders are split between buying the pullback on long-term electricity-demand and nuclear-power prospects and worrying about near-term regulatory uncertainty and weak price action.